We read with great interest the Article by John T Schiller and colleagues1 published in The Lancet Microbe; this Article reported the factors contributing to the potency of human papillomavirus (HPV) ...

We read with great interest the Article by John T Schiller and colleagues1 published in The Lancet Microbe; this Article reported the factors contributing to the potency of human papillomavirus (HPV) ...

The goal of the ECDC fellowship programme is to develop an European network of public health epidemiologists that share concepts and methods.

Respiratory syncytial virus (RSV) is a major cause of severe illness in infants and young children.We updated this systematic review to explore the ef…

We write to the editorial team regarding the recently published paper “Randomized clinical trials of COVID-19 vaccines: Do adenovirus-vector vaccines have beneficial non-specific effects?”1 by Benn et...

To describe the first documented case of Andes virus (ANDV) hantavirus cardiopulmonary syndrome (HCPS) in Spain and the first worldwide use of a therapeutic regime including two antivirals (favipiravi...

Here the authors characterize mRNA-based tuberculosis vaccine candidates BNT164a1 and BNT164b1 and show that they are immunogenic, well tolerated and efficacious in preclinical animal models.

Treatment with nirmatrelvir–ritonavir for acute COVID-19 was associated with a significant reduction in the risk of long COVID at 3 months’ follow-up. The limited sample size precludes firm conclusion...

npj Viruses - Wild carnivores in the Netherlands show molecular and serological evidence of West Nile virus and Usutu virus infection

Is syphilis a disease of the past?Not at all.In this Myth Busti...

The director-general of the World Health Organization is profoundly worried about the Ebola outbreak in the DRC, he told STAT in an interview.

Background Since 2023, two preventive tools (monoclonal antibodies, nirsevimab, and preF maternal vaccine) were approved to protect infants against severe RSV infections. During winter 2024–2025, nirs...

Background Since 2023, two preventive tools (monoclonal antibodies, nirsevimab, and preF maternal vaccine) were approved to protect infants against severe RSV infections. During winter 2024–2025, nirs...

Author Summary In this report we describe a newly discovered ebolavirus species which caused a large hemorrhagic fever outbreak in western Uganda. The virus is genetically distinct, differing by more ...

Clinical Literature Appraisal and Research education in InfecTious diseases

In 2017, the first autochthonous cases of tick-borne encephalitis (TBE) were reported in the region of Saint-Étienne, a forested and mountainous area …

Streptococcus pneumoniae is a causative agent of severe pneumonia, particularly in at-risk populations. To characterize immune responses elicited by t…

Streptococcus pneumoniae is a causative agent of severe pneumonia, particularly in at-risk populations. To characterize immune responses elicited by t…

YouTube video by ECDC

We read with attention the article by Ranque and Cogan (1) entitled "Internal medicine at the crossroads of Long COVID diagnosis and management." W...

The European Centre for Disease Prevention and Control (ECDC) assesses the risk to the general population in the European Union and European Economic Area (EU/EEA) of invasive meningococcal disease (I...

“Old habits die hard”: although an increasing body of evidence indicates that screening for asymptomatic bacterial sexually transmitted infections such as Neisseria gonorrhoeae and Chlamydia trachomat...

The European 2025/26 influenza season is dominated by the influenza A(H3N2) virus, with most sequenced viruses belonging to subclade K, genetically drifted from the vaccine virus, raising concerns around vaccine effectiveness (VE). Despite this, VE estimates from nine European studies (19 countries) indicate all-age influenza A VE of 25–45% for outpatient and hospital settings combined, similar to other seasons, with highest estimates among children (47–72%). Vaccination should be encouraged and complemented by other infection prevention and control measures.